OPTN Share Price Performance
US$9.60
3.30 (52.38%)
47.3% undervalued intrinsic discount
US$18.22
Fair Value
Price US$9.60
AnalystConsensusTarget US$18.22
Fair ValueUS$18.22
Share Pricen/a
OptiNose, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
OPTN Community Narratives
AN
Fair Value US$18.22 46.7% undervalued intrinsic discount
Improved Prescription Fulfillment And Primary Care Entry Will Unlock Opportunity
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
Improved Prescription Fulfillment And Primary Care Entry Will Unlock Opportunity
Key Takeaways Enhanced sales force execution and improved prescription fulfillment processes are expected to drive revenue growth through better market penetration. Refinement of co-pay assistance and focus on profitable prescriptions could improve net margins and ensure financial sustainability.Read more
11
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
US$18.22
46.7% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
20.43% p.a.
Profit Margin
20.04%
Future PE
9.66x
Price in 2028
US$11.95
Trending Discussion
Recently Updated Narratives
AN
Improved Prescription Fulfillment And Primary Care Entry Will Unlock Opportunity
Fair Value: US$18.22 46.7% undervalued intrinsic discount
5 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
OptiNose, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- -2.95
- 90.53%
- -36.52%
- -207.3%
About OPTN
- Founded
- 2000
- Employees
- 128
- CEO
- WebsiteView website
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase III clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
